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Edited by Lukas HuberAbstract MM-1 has been reported to repress the E-box-
dependent transcription activity of c-Myc by recruiting histone
deacetylase 1 complex via TIF1b/KAP1. In this study, to
identify target genes for c-Myc-MM-1-TIF1b, we established
rat-1 cells harboring the dominant-negative form of TIF1b to
abrogate the pathway from TIF1b to MM-1-c-Myc. This cell
line, in which transcription activity of c-Myc was activated, was
found to be tumorigenic. By DNA-microarray analysis of this
cell line, expression and promoter activity of the c-fms oncogene
were found to be upregulated. Of the two promoters, pE1 and
pE2, in the c-fms gene, pE1 promoter activity was found to be
activated in an E-box-dependent manner.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Transrepression1. Introduction
The proto-oncogene product c-Myc plays pivotal roles in
cell proliferation, diﬀerentiation and apoptosis induction, and
its levels are tightly regulated at several steps, including tran-
scription, translation and protein stability [1–3]. We have re-
ported that MM-1, a novel protein binding to the myc box II
located in the N-proximal region of c-Myc, suppressed tran-
scription and transformation activities of c-Myc and that
A157R mutation of c-Myc, which is observed at high fre-
quency in patients with lymphoma or leukemia, abrogated all
of the functions of MM-1 toward c-Myc, indicating that MM-
1 is a novel tumor suppressor [4,5]. As for the MM-1-depen-
dent transrepression pathway of c-Myc, we have shown that
MM-1 recruited histone deacetylase (HDAC) complex to c-
Myc via TIF1b, a corepressor [6]. MM-1 has been reported to
bind to p73, a member of the p53 family of proteins, to
modulate its function [7], and to be a component of the PFD/
Gim complex, a chaperon that carries unfolded proteins to a* Corresponding author. Fax: +81-11-706-4988.
E-mail address: hiro@pharm.hokudai.ac.jp (H. Ariga).
Abbreviations: HDAC1, histone deacetylase 1; HA, hemagglutinin
antigen; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; M-
CSF-1, macrophage colony stimulating factor; 4-OHT, 4-hydroxyl
tamoxifen
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ulated by the c-Myc-MM-1-TIF1b complex, we established a
ﬁbroblast cell line harboring a dominant-negative form of
TIF1b to abrogate this complex. The results showed that the c-
fms oncogene is a target gene for c-Myc-MM-1-TIF1b to be
suppressed in ﬁbroblast cell lines.2. Materials and methods
2.1. Establishment of cell lines
Rat Myc-ER cells cultured in Dulbecco’s modiﬁed Eagle’s medium
with 10% calf serum in the presence of 2.5 lg/ml of puromycin were
transfected with pEFTIF1bDN-HA, which expresses the C-terminal
region of TIF1b (TIF1bDN), possessing the region spanning amino
acid numbers 470–835 [6], or with pEF-HA together with pSV2-bsr, an
expression vector for blasticidin S, and the cells were cultured in the
medium in the presence of 8 lg/ml of blasticidin S for 14 days. The
cells that were resistant to the drug were then selected and expression
of the C-terminal region of TIF1b was examined by Western blotting
with an anti-hemagglutinin antigen (HA) antibody.
2.2. Luciferase activity
Reporter genes for the human c-fms gene promoters, pE1-Luc and
pE2-Luc [10], were kindly provided by E. Sapi. Myc-ER cell lines
harboring TIF1bDN subconﬂuent in a 6-cm dish were transfected with
1 lg of p4xE-SVP-Luc [4], pE1-Luc or pE2-Luc together with 1 lg of
pCMV-b-gal by the calcium phosphate precipitation method. Forty
eight hours after transfection, cell extracts were prepared and their
luciferase activities were examined after standardization of the trans-
fection eﬃciencies by b-galactosidase assays as described previously
[6].
2.3. RT-PCR and plasmid construction














RT-PCRs, to amplify cDNAs of rat c-fms or rat GAPDH, were
carried out using total RNA from Myc-ER cell lines with M-CSF-1-up
and M-CSF-1-down or with GAPDH-up and GAPDH-down as
templates and primers, respectively. Reporter plasmids of luciferase-
deletion mutants of the c-fms promoter were constructed usingation of European Biochemical Societies.
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primers, respectively.
2.4. Colony forming and tumor forming assays
Myc-ER cell lines were cultured in a medium containing agarose for
14 days as described previously [11]. A total of 1 107 Myc-ER cells
were injected subcutaneously into 6-week-old mice. Eight weeks after
injection, the numbers of tumors that had been developed in the mice
were counted.
2.5. Chromatin immunoprecipitation assays
Nucleotide sequences of the oligonucleotide used for PCR primers
were as follows:
ODC E-box up, 50-GGCACGTGTGCGCGCCTCGCC-30;
ODC E-box down, 50-AAATTGGTGTCATCTGCTCTGTAG-30;
ODC intron up, 50-GTTGTTACTCTCTTCCCTTCTCCG-30;
ODC intron down, 50-ATAATTTGGGGCTAACTTCACCAA-30;
c-fms E-box up, 50-AGGCTCTGGTGCTGAGGCGT-30;
c-fms E-box down, 50-CTGAGATGCTGCAGCCGTGA-30;
c-fms intron up, 50-AGTGACCTGAGTCCTACTACTAT-30;
c-fms intron down, 50-CTGAGTCACATCACAGGACT-30.
Chromatin immunoprecipitation (Chip) assays were carried out us-
ing HeLa nuclear extract and the above primers according to the
supplier’s protocol (Chip Assay Kit, Upstate).3. Results and discussion
3.1. Activation of c-myc promoter in cells harboring a
dominant-negative form of TIF1b
MycER cells are Rat-1 cells harboring a chimeric protein of
c-Myc fused with the estrogen receptor (MycER), and MycER
complexed with Hsp90 is localized in the cytoplasm in the
absence of 4-hydroxyl tamoxifen (4-OHT), thereby inactivat-
ing transcription activity of Myc-ER. After addition of 4-OHTFig. 1. Establishment of a cell line harboring a dominant-negative form of T
(MycER-TIF1DN cells) or vector alone (MycER-vec cells) were established a
and GAPDH in these cells cultured in the presence of 4-OHT was analyzed b
anti-GAPDH antibody (Chemicon). (B) MycER, MycER-vec and MycER-T
Forty eight hours after transfection, cell extracts were prepared and their lucif
experiments were carried out.to the medium, Myc-ER is translocated into the nucleus to be
activated [12]. MycER cells have therefore been used for an
Myc-speciﬁc expression system. In order to identify target
genes for the c-Myc-MM-1-TIF1b complex, MycER cells were
transfected with expression vectors for the HA-tagged C-ter-
minal region of TIF1b (TIF1bDN-HA), which is a dominant-
negative form of TIF1b [6], or a vector alone together with
blasticidin S. Blasticidin S-resistant cells were then selected and
expression of TIF1bDN-HA in each cell line was examined by
Western blotting using an anti-HA-antibody (Fig. 1A). While
protein concentrations determined by amounts of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) were almost the
same in the cell lines, TIF1bDN-HA was expressed in MycER
cells transfected with TIF1bDN-HA (MycER-TIF1DN cells)
but not in parental MycER and MycER cells transfected with
a vector alone (MycER-vec cells). It was conﬁrmed that
amounts of TIF1bDN-HA in MycER-TIF1DN cells did not
change in the presence or absence of 4-OHT as described
previously [12]. The amounts of endogenously expressed
TIF1b and c-Myc also did not change in each cell line (data
not shown). To examine the transcription activity of c-Myc,
these cell lines cultured in the presence or absence of 4-OHT
were transfected with reporter genes containing the 4 x E-box
linked to the luciferase gene and their luciferase activities were
examined 48 h after transfection (Fig. 1B). In the absence of 4-
OHT, the luciferase activity level of MycER-TIF1DN cells was
found to be higher than that of MycER or MycER-vec cells as
in the case of transient transfection experiments [6], indicating
that transcription activity of endogenous-Myc was stimulated
in MycER-TIF1DN cells, in which repressed transcription
activity of c-Myc by MM-1-TIF1b complex was abrogated byIF1b. (A) Myc ER cell lines harboring the C-terminal region of TIF1b
s described in Section 2. Expression of the C-terminal region of TIF1b
y Western blotting using an anti-HA antibody (12CA5, Roche) and an
IF1DN cells were transfected with p4xE-box-SVP-Luc and pSV-b-gal.
erase activities were examined as described in Section 2. More than ﬁve
A. Satou et al. / FEBS Letters 572 (2004) 211–215 213TIF1DN. Since exogenously added Myc-ER was activated by
4-OHT, the results also showed that transcription activities of
c-Myc in all of the MycER cell lines were stimulated by 4-OHT
and that transcription activity of c-Myc in MycER-TIF1DN
cells was a sum of activities of endogenous c-Myc and exoge-
nous MycER.
To characterize MycER-TIF1DN cells in terms of onco-
genesis, MycER-TIF1DN and MycER-vec cells were cultured
in a medium containing agarose in the absence of 4-OHT. The
results showed that MycER-TIF1DN grew and formed colo-
nies, while MycER-vec cells died (Fig. 2A). Furthermore,
when MycER-TIF1DN and MycER-vec cells were injected
subcutaneously into mice, only MycER-TIF1 DN cells were
found to induce tumors (Fig. 2B). MycER-TIF1 DN cells
cultured in the presence of 4-OHT were also found to give
colonies in soft agar medium and to induce tumors more than
did MycER-TIF1DN cells cultured in the absence of 4-OHT
(data not shown), which was parallel with transcription ac-
tivity of c-Myc as described in Fig. 1B. Although eﬃciencies of
MycER-TIF1DN cells to form colonies and tumors were found
not to be high compared to those of cells transformed with c-
myc and activated H-ras genes, these results suggest that
MycER-TIF1DN cells are tumorigenic and that stimulated
transcription activity of c-Myc leads to upregulation of some
genes that are related to cell transformation.Fig. 2. Tumorigenicity of MycER-TIF1DN cells. (A) MycER-vec and
MycER-TIF1DN cells were cultured in a medium containing agarose,
and colonies formed were examined at 14 days after seeding. Photo-
graphs of cells are shown. (B) 107 MycER-vec and MycER-TIF1DN
cells were injected subcutaneously into 6-week-old mice. Photographs
of tumors that had developed in the mice at eight weeks after injection
are shown. Two experiments were carried out both in (A) and (B).3.2. Identiﬁcation of the c-fms oncogene as a target gene for the
c-Myc-MM-1-TIF1b pathway
To identify genes whose expressions are upregulated in
MycER-TIF1DN cells, DNA-microarray analysis of genes
between MycER-TIF1DN and MycER-vec cells was carried
out using a Rat microarray glass ﬁlter, in which 1081 genes
were spotted (Rat 1.0 Microarray, Clontech). Five genes were
found to be expressed at levels more than 2.5-times higher in
MycER-TIF1DN cells than in MycER-vec cells, and expres-
sions of these genes were further examined by RT-PCR using
total RNAs from both cell lines. The results showed that of the
ﬁve genes, expression of the c-fms gene, which encodes mac-
rophage colony stimulating factor 1 (M-CSF-1) receptor, was
reproducibly stimulated in MycER-TIF1DN cells (Fig. 3A). ItFig. 3. Activation of c-Myc transcription activity in MycER-TIF1 DN
cells. (A) Total RNAs were extracted from MycER and MycER-
TIF1DN cells, and expression of c-fms and GAPDH genes was ana-
lyzed by RT-PCR as a described in Section 2. After 10 cycles of PCR,
DNAs extracted from the mixtures were analyzed by Southern blotting
using 32P-labeled cDNAs of c-fms and GAPDH genes as probes. (B)
Schematic drawing of the promoter region of the human c-fms gene.
(C) MycER and MycER-TIF1DN cells were transfected with pE1 or
E2-Luc and pSV-b-gal. Forty eight hours after transfection, cell ex-
tracts were prepared and their luciferase activities were examined as
described in Section 2. Five experiments were carried out.
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phage and myeloid cells and weakly in ﬁbroblast cells such as
Rat-1 cells and that overexpression of the c-fms gene trans-
forms macrophage and myeloid cells [13–15]. The human andFig. 4. Identiﬁcation of the E-box sequence for expression of the c-fms gene i
human c-fms gene. Squares indicate E-box sequences. (B) A schematic drawin
the ﬁgure. MycER, MycER-vec and MycER-TIF1DN cells were transfected w
transfection, cell extracts were prepared and their luciferase activities were me
Chip assays were carried out using HeLa cell extracts and primers speciﬁc to
gene was schematically described and the regions ampliﬁed by PCR with spe
Nucleotide numbers indicated at both ends of primers correspond to those in
previously [18]. The nuclear extracts containing chromatin were prepared fr
(C33, Santa Cruz) or non-speciﬁc IgG according to the supplier’s protocol (C
from the mixtures and speciﬁc primers as described in Section 2. The prod
visualized under UV-light.mouse c-fms genes contain two promoters, pE1 and pE2, and
these are necessary for the c-fms gene to be expressed speciﬁ-
cally in ﬁbroblastic cells, including placental trophoblasts and
mammary gland, and myeloid cells, respectively [10] (Fig. 3B).n MycER cells. (A) Nucleotide sequence of the promoter region of the
g of deletion mutants of the pE1 promoter is shown in the upper part of
ith deletion mutants of pE1-Luc and pSV-b-gal. Forty eight hours after
asured as described in Section 2. Five experiments were carried out. (C)
an exon and intron of human c-fms and ODC genes. The human c-fms
ciﬁc primers in the c-fms gene, E-box and Intron, were also described.
A. The regions to be ampliﬁed by PCR in the ODC gene were described
om HeLa cells and immunoprecipitated with an anti-c-Myc antibody
hip Assay Kit, Upstate). PCR was carried out using DNAs extracted
ucts were then run on agarose gels containing ethidium bromide and
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TIF1DN cells, reporter genes containing pE1 or pE2 linked to
the luciferase gene were transfected into MycER and MycER-
TIF1DN cells and their luciferase activities were examined
(Fig. 3C). The results clearly showed weak luciferase activities
of pE2 in both cell lines compared to those of pE1 even in the
presence of 4-OHT, which activates transcription activity of
MycER. Promoter activities of pE1 in MycER cells were found
to be stimulated by 4-OHT in a dose-dependent manner, and
those in MycER-TIF1DN cells in the absence of 4-OHT, on
the other hand, were found to be higher than those in MycER
cells in the presence of 1 mM 4-OHT (Fig. 3C). These results
suggest that transcription activity of the c-fms gene in MycER
cells depends on pE1 and that abrogation of the c-Myc-MM-1-
TIF1b pathway stimulates pE1 activity.
A search for recognition sequences for transcription factors
in the E1 promoter region of the human c-fms gene was made,
and three E-box sequences, which are candidates for the rec-
ognition sequence of c-Myc, were identiﬁed (Fig. 4A). These
were termed E-box 1, E-box 2 and E-box 3, and the E-box 3
contains two E-box sequences. To identify the E-box that
contributes to expression of the c-fms gene in MycER cells,
deletion mutants of reporter genes lacking each E-box se-
quence, pE1DE-box 1, pE1DE-box 2 and pE1DE-box 3, were
constructed and their promoter activities were examined after
transfection of these reporter genes into MycER cell lines
(Fig. 4B). The results clearly showed that while promoter ac-
tivities of pE1DE-box 1 and pE1DE-box 2 did not change, or
rather were stimulated, compared to those of the wild-type E1
promoter, promoter activity of pE1DE-box 3 lacking the E-
box 3 was found to decrease in all of the cell lines, indicating
that the E-box 3 is responsible for the E1 promoter in MycER
cells. Furthermore, to determine whether c-Myc binds to the
region containing the E-box in the c-fms gene, chromatin im-
munoprecipitation assays were carried out using HeLa cell
extracts. Since reporter gene assays described above used the
human c-fms gene and the genomic structure of the rat c-fms
gene has not been characterized, we used HeLa cells for
chromatin immunoprecipitation assays. Expression of the c-
fms gene was not detected in HeLa cells and primers that
amplify the regions corresponding to the E-box or intron of
the human c-fms or ornitin decarboxylase (ODC) gene as a
positive control (Fig. 4C). The results showed that an anti-c-
Myc antibody but not non-speciﬁc IgG precipitated regions
containing E-box sequences of c-fms and ODC genes, while the
anti-c-Myc antibody did not precipitate intron sequences of c-
fms and ODC genes. Furthermore, gel mobility shift assays
showed that puriﬁed c-Myc and Max bound to the E-box 3
(data not sown). These results indicate that c-Myc binds to E-
box sequences of both genes.
In this study,we identiﬁed the c-fms oncogene that is regu-
lated by the c-Myc-MM-1-TIF1b complex through the E-box
sequence in ﬁbroblasts. Abrogation of this pathway in RatER
cells, a ﬁbroblast cell line, resulted in the cells becoming tu-
morigenic with strong transcription activity of c-Myc. Sincethe c-fms gene is usually expressed in macrophage or myeloid
cells and overexpression of the c-fms gene transforms these
cells [13–15], these ﬁndings suggest that the MM-1-TIF1b
complex plays a role in suppression of oncogenes that are not
expressed or only weakly expressed in cells other than myeloid
cells and also that contain an E-box sequence, a recognition
sequence for c-Myc. The ﬁndings in this study also suggest that
even when c-Myc binds to the E-box sequence in these onc-
ogenes, the MM-1-TIF1b complex suppresses c-Myc tran-
scription activity, thereby preventing cells from becoming
tumorigenic.
Although transrepression pathways through basic-helix-
loop-helix-zip domains in the C-terminal region of c-Myc have
been well characterized, those from the N-terminal region
containing myc box I and myc box II domains have not been
well investigated. From this point of view, MM-1 is thought to
be the most characterized protein that binds to the N-terminal
transrepression region of c-Myc. In addition to MM-1, two
proteins, Pag [16] and Krim1 [17], that have characteristics
similar to those of MM-1, have been reported. Although target
genes for Pag and Krim1 have not been identiﬁed, investiga-
tion of these proteins, including MM-1, should shed light on
the repression pathway from the N-terminal region of c-Myc.
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